青霉素用于急诊科门诊治疗蜂窝织炎的PEDOCELL试验:研究方案更新与详细统计分析计划(SAP)
PEDOCELL试验是一项多中心、随机、平行组、双盲、非劣效性临床试验,比较氟氯西林单药与氟氯西林/苯氧甲基青霉素联合方案在急诊科门诊治疗蜂窝织炎的疗效。本文介绍该试验预先制定的详细统计分析计划,旨在减少分析偏倚、防止结局报告偏倚和选择性报告。
要点
- PEDOCELL试验比较口服氟氯西林单药与氟氯西林/苯氧甲基青霉素联合方案治疗急诊科门诊蜂窝织炎。
- 主要结局为治愈访视时研究者判定的临床反应,采用非劣效性设计。
- 统计分析计划预先制定,旨在减少分析偏倚和选择性报告。
核心结论
- 该试验旨在确立口服氟氯西林单药相对于口服氟氯西林/苯氧甲基青霉素联合方案在急诊科门诊治疗蜂窝织炎中的非劣效性。
- 统计分析计划预先制定以尽量减少分析偏倚。
研究设计与样本
- 多中心、随机、平行组、双盲、非劣效性临床试验。
- 患者随机接受口服氟氯西林500 mg每日四次加安慰剂,或口服氟氯西林500 mg每日四次加苯氧甲基青霉素500 mg每日四次。
- 试验包括7天干预期和2周随访期,在入组时、入组后2-3天(早期临床反应访视)、入组后8-10天(治疗结束访视)和入组后14-21天(治愈访视)四个时间点进行测量。
主要发现
- 主要结局指标为治愈访视时研究者判定的临床反应。
- 次要结局包括早期临床反应访视时的病灶大小、每次随访时的临床治疗失败、治疗结束访视时口服抗生素治疗的依从性和持续性、健康相关生活质量(HRQoL)和药物经济学评估。
关键数值与推荐
- 主要结局为治愈访视时研究者判定的临床反应。
- 次要结局包括早期临床反应访视时的病灶大小、每次随访时的临床治疗失败、治疗结束访视时口服抗生素治疗的依从性和持续性、健康相关生活质量(HRQoL)和药物经济学评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cellulitis is a painful, potentially serious, infectious process of the dermal and subdermal tissues and represents a significant disease burden. The statistical analysis plan (SAP) for the Penicillin for the Emergency Department Outpatient treatment of CELLulitis (PEDOCELL) trial is described here. The PEDOCELL trial is a multicentre, randomised, parallel-arm, double-blinded, non-inferiority clinical trial comparing the efficacy of flucloxacillin (monotherapy) with combination flucloxacillin/phenoxymethylpenicillin (dual therapy) for the outpatient treatment of cellulitis in the emergency department (ED) setting. To prevent outcome reporting bias, selective reporting and data-driven results, the a priori-defined, detailed SAP is presented here. METHODS/DESIGN: Patients will be randomised to either orally administered flucloxacillin 500 mg four times daily and placebo or orally administered 500 mg of flucloxacillin four times daily and phenoxymethylpenicillin 500 mg four times daily. The trial consists of a 7-day intervention period and a 2-week follow-up period. Study measurements will be taken at four specific time points: at patient enrolment, day 2-3 after enrolment and commencing treatment (early clinical response (ECR) visit), day 8-10 after enrolment (end-of-treatment (EOT) visit) and day 14-21 after enrolment (test-of-cure (TOC) visit). The primary outcome measure is investigator-determined clinical response measured at the TOC visit. The secondary outcomes are as follows: lesion size at ECR, clinical treatment failure at each follow-up visit, adherence and persistence of trial patients with orally administered antibiotic therapy at EOT, health-related quality of life (HRQoL) and pharmacoeconomic assessments. The plan for the presentation and comparison of baseline characteristics and outcomes is described in this paper. DISCUSSION: This trial aims to establish the non-inferiority of orally administered flucloxacillin monotherapy with orally administered flucloxacillin/phenoxymethylpenicillin dual therapy for the ED-directed outpatient treatment of cellulitis. In doing so, this trial will bridge a knowledge gap in this understudied and common condition and will be relevant to clinicians across several different disciplines. The SAP for the PEDOCELL trial was developed a priori in order to minimise analysis bias. TRIAL REGISTRATION: EU Clinical Trials Register (EudraCT number: 2016-001528-69). Registered on 5 April 2016. ClinicalTrials.gov, ID: NCT02922686 . Registered on 9 August 2016.
引用
- Boland F, Quirke M, Gannon B, et al. The Penicillin for the Emergency Department Outpatient treatment of CELLulitis (PEDOCELL) trial: update to the study protocol and detailed statistical analysis plan (SAP). Trials. 2017. PMID: 28836993. doi:10.1186/s13063-017-2121-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。